Trevena Inc
Re: Trevena Inc
- cashpositie van iets over de 100m USD waarmee ze tot eind 2022 verder kunnen.
- product net op de markt, IV opioid op basis van kratom met wat minder bijwerkingen
- omzet oploop dus verwacht dit jaar, moet per ziekenhuisgroep in de VS goedgekeurd worden op het formulary (dus wat een dokter in dat ziekenhuis kan gebruiken) en dit gaat meestal wel trager dan een investeerder zou willen.
- grote generieke opioid spelers
Searching sexy stock 2 stay in my portfolio. Req:YoY 120% return,Ready to be sold off to strangers,At least 30% shorted of the float.Symbol can't start with S,P or A. In return will pump and dump you.
Laatste artikelen op Beursig.com
Beleggen in bitcoin en ethereum op Euronext beurs
Wild west taferelen bij aandelen, crypto valuta en ...
Volg Beursig.com
Re: Trevena Inc
Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Download as PDFFebruary 22, 2021 7:00am EST
CHESTERBROOK, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 a.m. EST.
Presentation Details
Date: Friday, February 26, 2021
Time: 8:40 a.m. Eastern Time
Presenter: Bob Yoder, Senior Vice President and Chief Commercial Officer
Webcast: https://wsw.com/webcast/svbleerink47/trvn/2707456
A link to the webcast will be available on the Events page of the Investors section on the Company’s website at www.trevena.com/investors/events-presen ... r-calendar.
Download as PDFFebruary 22, 2021 7:00am EST
CHESTERBROOK, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 a.m. EST.
Presentation Details
Date: Friday, February 26, 2021
Time: 8:40 a.m. Eastern Time
Presenter: Bob Yoder, Senior Vice President and Chief Commercial Officer
Webcast: https://wsw.com/webcast/svbleerink47/trvn/2707456
A link to the webcast will be available on the Events page of the Investors section on the Company’s website at www.trevena.com/investors/events-presen ... r-calendar.
Searching sexy stock 2 stay in my portfolio. Req:YoY 120% return,Ready to be sold off to strangers,At least 30% shorted of the float.Symbol can't start with S,P or A. In return will pump and dump you.
-
piddybull
- waarderingen: 2
Re: Trevena Inc
Trevena Stock Could Triple Form Here, Says Analyst
Marty Shtrubel
May 11, 2021, 11:12 PM
There is a lot to like right now about Trevena (TRVN), says H.C. Wainwright analyst Douglas Tsao.
Tsao’s positive thesis for the drug maker is based on the latest developments regarding Olinvyk, the company’s opioid agonist which last year gained FDA approval for the treatment of moderate to severe acute pain in adults. The drug was launched earlier this year, and all is going swimmingly so far.
“Even though the Olinvyk field force has only been active since February and mostly through digital channels, Trevena has already achieved 10 formulary wins and had 60 accounts in various stages of review as it makes progress toward a goal of 100 wins by the end of the year,” the analyst said.
The goal is reasonable enough, according to Tsao, who also believes the wins are a strong indication the drug is “gaining traction.” Although, to date, the “digital engagements” have been relatively successful, and brought contact with 98% of the target audience – far higher than the industry average – Tsao thinks that as more sales calls are done in person, the pace of wins will pick up, with “the latest proportion increasing to 70%.”
Additionally, a new clinical outcome study is slated to launch in 3Q, which will further showcase Olinvyk’s safety profile.
The open-label study will enroll approximately 200 patients and will further define “safety outcomes in the postoperative setting” vs. historic opioid data. The “prestigious” Cleveland Clinic will take charge of the study.
As data for this type of drug class is generally “sparse” and there is no consensus on methodology, Tsao is excited about the use of new continuous monitoring technology for the respiratory safety assessment. Another element to look out for will be the “cognitive function outcome” – in earlier studies, investigators had “anecdotally observed a benefit.”
“Though it is still unclear if this data can be used for a label expansion or be added to the label, another safety assessment should bolster Olinvyk’s already strong body of published literature and could catalyze further formulary wins,” the analyst further noted.
Tsao’s confidence in Trevena’s success is confirmed by a Buy rating and $5 price target. The implication for investors? Investors stand to pocket ~218% gain should the analyst’s thesis play out. (To watch Tsao’s track record, click here)
The rest of the Street has no doubts concerning Trevena’s prospects, either. TRVN’s Strong Buy consensus rating is backed by 3 Buys and 1 Hold. The average price target stands at $5.33, and implies possible upside of ~239% over the next year.
Marty Shtrubel
May 11, 2021, 11:12 PM
There is a lot to like right now about Trevena (TRVN), says H.C. Wainwright analyst Douglas Tsao.
Tsao’s positive thesis for the drug maker is based on the latest developments regarding Olinvyk, the company’s opioid agonist which last year gained FDA approval for the treatment of moderate to severe acute pain in adults. The drug was launched earlier this year, and all is going swimmingly so far.
“Even though the Olinvyk field force has only been active since February and mostly through digital channels, Trevena has already achieved 10 formulary wins and had 60 accounts in various stages of review as it makes progress toward a goal of 100 wins by the end of the year,” the analyst said.
The goal is reasonable enough, according to Tsao, who also believes the wins are a strong indication the drug is “gaining traction.” Although, to date, the “digital engagements” have been relatively successful, and brought contact with 98% of the target audience – far higher than the industry average – Tsao thinks that as more sales calls are done in person, the pace of wins will pick up, with “the latest proportion increasing to 70%.”
Additionally, a new clinical outcome study is slated to launch in 3Q, which will further showcase Olinvyk’s safety profile.
The open-label study will enroll approximately 200 patients and will further define “safety outcomes in the postoperative setting” vs. historic opioid data. The “prestigious” Cleveland Clinic will take charge of the study.
As data for this type of drug class is generally “sparse” and there is no consensus on methodology, Tsao is excited about the use of new continuous monitoring technology for the respiratory safety assessment. Another element to look out for will be the “cognitive function outcome” – in earlier studies, investigators had “anecdotally observed a benefit.”
“Though it is still unclear if this data can be used for a label expansion or be added to the label, another safety assessment should bolster Olinvyk’s already strong body of published literature and could catalyze further formulary wins,” the analyst further noted.
Tsao’s confidence in Trevena’s success is confirmed by a Buy rating and $5 price target. The implication for investors? Investors stand to pocket ~218% gain should the analyst’s thesis play out. (To watch Tsao’s track record, click here)
The rest of the Street has no doubts concerning Trevena’s prospects, either. TRVN’s Strong Buy consensus rating is backed by 3 Buys and 1 Hold. The average price target stands at $5.33, and implies possible upside of ~239% over the next year.
Re: Trevena Inc
-20% overdreven of niet?
Re: Trevena Inc
Wie had dit verwacht?????
En enkel omdat ze een goedkeuring kregen voor China voor een product dat ze in Amerika aan de straatstenen niet kwijtgeraken.
2.8700+2.2251 (+345.03%)
Zwaar verlies gepakt tussen 0.998 en 1.198 in de hoop ze later goedkoper terug te kunnen kopen, had ik ze nog gehad...
En enkel omdat ze een goedkeuring kregen voor China voor een product dat ze in Amerika aan de straatstenen niet kwijtgeraken.
2.8700+2.2251 (+345.03%)
Zwaar verlies gepakt tussen 0.998 en 1.198 in de hoop ze later goedkoper terug te kunnen kopen, had ik ze nog gehad...
